Литература

1. Исследование TNS-NIPO «Особенности женской сексуальности», 2005 год.
2. Прилепская В.Н. Руководство по контрацепции. М: МЕДпресс-информ, 2006.—с.141-148.
3. Чернышева Е.С. Применение контрацепции в пролонгированном режиме с лечебной целью ЖРОАГ, 4/2009
4. Bjarnadottir RI et al. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrautrine contraceptive device in lactating women. Br J Obstet Gynaecol 2001; 108: 1174-80.
5. Backstrom T, Hansson-Malmstrom Y, Lindhe B A, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992; 46; 3: 253-68.
6. Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive. Drug Res 1988; 38: 932 4.
7. Collaborative study group on the desogestrel-containing progestagen-only Pill. Eur J Contracept Reproduct Health Care 1998; 3: 169-78 .
8. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring Obstet Gynecol. 2002; 100:585-93.
9. Family planning. A global handbook for providers. WHO, 2007.
10. Ferguson H, Vree ML, Wilpshaar J, Eskes TKAB. Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive. Eur J Contracept Reprod Health Care 2000; 5:35-45
11. International marketing data Organon 2005
12. Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TCJ. Effects of a phasic desogestrel-containing oral contraceptive on facial seborrhoea and acne. Eur J Contracept Reprod Health Care 2000; 5:1-8
13. Lammers P, Op ten Berg M. Phase III clinical trial with new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70: 497 500.
14. Nabrink M, Birgereson L, Colling-Saltin A S, et al. Modern oral contraceptives and dysmenorrhoea. Contraception 1990; 42: 275-83.
15. Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinylestradiol and desogestrel. Acta Obstet Gynaecol Scand 1988; 67: 171 4.
16. Roumen FJME, Apter D, Mulders TMT, Dieben TOM. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethynilestradiol. Hum Reprod 2001; 16: 469-75
17. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186:1142-9.
18. The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005;11(5): 513–525.
19. WHO, Medical eligibility criteria for contraceptive use, 2008
20. А.Л.Верткин, О.Б.Талибов. Генерики и эквивалентность — что стоит за терминами. Неотложная терапия, 2004, № 1-2, с.16-17
21. Мелихов О.Г. Клинические исследования. Москва, 2003, с.198.
22. Серов В.Н. Терапия урогенитальных расстройств, обусловленных дефицитом эстрогенов. 2010; 1: 21-35
23. Сметник В.П. Медицина климактерия. Москва, 2006, с. 847.